US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chemomab Therapeutics Ltd.

1.09

0.0000

Post-market: 1.08-0.0100-0.92%16:05 EDT

Volume:129.41K

Turnover:142.31K

Market Cap:20.89M

PE:-1.64

High:1.12

Open:1.08

Low:1.08

Close:1.09

Loading ...

Overview Company News Filings

Chemomab Therapeutics Ltd. Conducted Annual General Shareholders Meeting

Chemomab Therapeutics Announces Positive Phase 2 Trial Results for Nebokitug, Advancing Towards Phase 3 for Primary Sclerosing Cholangitis Treatment

Chemomab Therapeutics Secures FDA Alignment on CMC and Toxicology Milestones, Advancing Phase 3 Development of Nebokitug for PSC

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

THOMSON REUTERS

Chemomab Therapeutics Ltd - New Patents Cover Nebokitug Used for Treatment of Liver Diseases up to 2041

THOMSON REUTERS

Chemomab Therapeutics Ltd - Awarded New Patent Protections for Nebokitug in China and Russia

THOMSON REUTERS

Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis

Chemomab Therapeutics Ltd. : Oppenheimer Cuts Target Price to $10 From $11

THOMSON REUTERS

UPDATE: Chemomab Therapeutics Q1 EPADS $(0.14) Misses $(0.10) Estimate

Chemomab Therapeutics Q1 EPS $(0.007) Up From $(0.014) YoY

Chemomab Therapeutics Reports Q1 2025 Net Loss of $3.3 Million, EPS Remains Less Than $0.01

Press Release: Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

Chemomab Therapeutics Ltd expected to post a loss of 1 cent a share - Earnings Preview

Biotech Alert: Searches spiking for these stocks today

Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment

MT Newswires Live

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer

MT Newswires Live

Chemomab Announces New Medical and Clinical Appointments

BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CMMB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CMMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMMB\",,,,,undefined,":{"symbol":"CMMB","market":"US","secType":"STK","nameCN":"Chemomab Therapeutics Ltd.","latestPrice":1.09,"timestamp":1753473600000,"preClose":1.09,"halted":0,"volume":129407,"hourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.09,"latestTime":"16:05 EDT","volume":2641,"amount":2844.31,"timestamp":1753473940832},"delay":0,"floatShares":15103945,"shares":19163759,"eps":-0.666586,"marketStatus":"Market Closed","change":0,"latestTime":"07-25 16:00:00 EDT","open":1.08,"high":1.1193,"low":1.08,"amount":142307.9809,"amplitude":0.036055,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.666586,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"adrRate":20,"listingDate":1549947600000,"exchange":"NASDAQ","adjPreClose":1.09,"preHourTrading":{"tag":"盘前","latestPrice":1.08,"preClose":1.09,"latestTime":"08:13 EDT","volume":399,"amount":430.92,"timestamp":1753445594627},"postHourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.09,"latestTime":"16:05 EDT","volume":2641,"amount":2844.31,"timestamp":1753473940832},"volumeRatio":0.9552517557192065},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMMB\",,,,,undefined,":{"symbol":"CMMB","floatShares":15103945,"roa":"-57.49%","roe":"-112.97%","lyrEps":-0.776774,"volumeRatio":0.9552517557192065,"shares":19163759,"dividePrice":0,"high":1.1193,"amplitude":0.036055,"preClose":1.09,"low":1.08,"week52Low":0.87,"pbRate":"2.01","week52High":2.55,"institutionHeld":0,"latestPrice":1.09,"eps":-0.666586,"divideRate":0,"volume":129407,"delay":0,"ttmEps":-0.666586,"open":1.08,"prevYearClose":1.81,"prevWeekClose":1.13,"prevMonthClose":1.16,"prevQuarterClose":1.16,"fiveDayClose":1.13,"twentyDayClose":1.1936,"sixtyDayClose":1.28},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CMMB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548688211","title":"Chemomab Therapeutics Ltd. Conducted Annual General Shareholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2548688211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548688211?lang=en_us&edition=fundamental","pubTime":"2025-07-02 04:06","pubTimestamp":1751400382,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd. held its annual general shareholders meeting on July 1, 2025. Shareholders approved the re-election of Dr. Nissim Darvish and Ms. Jill Quigley as Class I directors. They also approved a grant of restricted share units to Dr. Adi Mor, the Chief Executive Officer and Chief Scientific Officer. Additionally, Somekh Chaikin was re-appointed as the independent registered public accounting firm for the fiscal year ended December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 01, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL9fyr6s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB","BK4139"],"gpt_icon":0},{"id":"2547099814","title":"Chemomab Therapeutics Announces Positive Phase 2 Trial Results for Nebokitug, Advancing Towards Phase 3 for Primary Sclerosing Cholangitis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2547099814","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547099814?lang=en_us&edition=fundamental","pubTime":"2025-06-30 20:00","pubTimestamp":1751284816,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Announces Positive Phase 2 Trial Results for Nebokitug, Advancing Towards Phase 3 for Primary Sclerosing Cholangitis Treatment. Chemomab Therapeutics Ltd. has announced the presentation of positive Phase 2 clinical data for their investigational drug, nebokitug, at BSG Live'25, the annual scientific meeting of the British Society for Gastroenterology in Glasgow, UK. The data, from the SPRING trial, indicates that nebokitug is well-tolerated and associated with significant improvements in fibrotic and inflammatory biomarkers in patients with primary sclerosing cholangitis . These improvements suggest a potential slowing of disease progression. The findings support the advancement of nebokitug to a Phase 3 trial, positioning it as a potential first-in-class treatment for PSC. The results were presented by Professor Douglas Thorburn, the Principal Investigator of the SPRING trial.Disclaimer: This news brief was created by Public Technologies  using generative artific","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL94jmhZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4585","LU2210150020.SGD","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","BK4139","CMMB","BK4588","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2542581934","title":"Chemomab Therapeutics Secures FDA Alignment on CMC and Toxicology Milestones, Advancing Phase 3 Development of Nebokitug for PSC","url":"https://stock-news.laohu8.com/highlight/detail?id=2542581934","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542581934?lang=en_us&edition=fundamental","pubTime":"2025-06-11 20:01","pubTimestamp":1749643262,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Secures FDA Alignment on CMC and Toxicology Milestones, Advancing Phase 3 Development of Nebokitug for PSC. TEL AVIV, Israel, June 11, 2025 -- Chemomab Therapeutics Ltd. , a clinical stage biotechnology company, announced positive feedback from two recent meetings with the FDA, facilitating the advancement of their drug nebokitug into a Phase 3 clinical trial for Primary Sclerosing Cholangitis . The FDA has aligned with Chemomab on essential Chemistry, Manufacturing, and Controls  requirements, ensuring the quality and consistency of the drug supply, and has also agreed to allow non-clinical toxicology studies to proceed concurrently with the Phase 3 clinical trial. This regulatory progress supports the timely advancement of nebokitug's development program as Chemomab continues discussions with potential strategic partners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL9QjQDs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","IE00B3QW5Z07.USD","CMMB","BK4588","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","NDAQ","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2542581616","title":"Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2542581616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542581616?lang=en_us&edition=fundamental","pubTime":"2025-06-11 20:00","pubTimestamp":1749643219,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nFWN3SE0GX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMMB","BK4139"],"gpt_icon":0},{"id":"2540779779","title":"Chemomab Therapeutics Ltd - New Patents Cover Nebokitug Used for Treatment of Liver Diseases up to 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2540779779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540779779?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:09","pubTimestamp":1748952597,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60EL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMMB"],"gpt_icon":0},{"id":"2540377929","title":"Chemomab Therapeutics Ltd - Awarded New Patent Protections for Nebokitug in China and Russia","url":"https://stock-news.laohu8.com/highlight/detail?id=2540377929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540377929?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:09","pubTimestamp":1748952597,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMMB"],"gpt_icon":0},{"id":"2540934779","title":"Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2540934779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540934779?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:00","pubTimestamp":1748952049,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis. Chemomab Therapeutics Ltd. has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis , with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL2vkPky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","CMMB","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","BK4588","IE00BKPKM429.USD","BK4139","LU2095319765.USD","BK4112","NDAQ","LU2210150020.SGD"],"gpt_icon":0},{"id":"2535394677","title":"Chemomab Therapeutics Ltd. : Oppenheimer Cuts Target Price to $10 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2535394677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535394677?lang=en_us&edition=fundamental","pubTime":"2025-05-16 20:16","pubTimestamp":1747397811,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nAZN3UG53J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMMB","BK4139"],"gpt_icon":0},{"id":"2535825946","title":"UPDATE: Chemomab Therapeutics Q1 EPADS $(0.14) Misses $(0.10) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535825946","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535825946?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:26","pubTimestamp":1747315588,"startTime":"0","endTime":"0","summary":"UPDATE: Chemomab Therapeutics Q1 EPADS $(0.14) Misses $(0.10) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45437087/update-chemomab-therapeutics-q1-epads-0-14-misses-0-10-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","BK4139","CMMB"],"gpt_icon":0},{"id":"2535842512","title":"Chemomab Therapeutics Q1 EPS $(0.007) Up From $(0.014) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535842512","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535842512?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:10","pubTimestamp":1747311021,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Q1 EPS $(0.007) Up From $(0.014) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45434595/chemomab-therapeutics-q1-eps-0-007-up-from-0-014-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB","LENZ"],"gpt_icon":0},{"id":"2535434844","title":"Chemomab Therapeutics Reports Q1 2025 Net Loss of $3.3 Million, EPS Remains Less Than $0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2535434844","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535434844?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:02","pubTimestamp":1747310559,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL8wkZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB"],"gpt_icon":0},{"id":"2535844435","title":"Press Release: Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535844435","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535844435?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:00","pubTimestamp":1747310400,"startTime":"0","endTime":"0","summary":"--Reported Positive 48-Week Data from SPRING Trial--Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis--. --Aligned with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a Single, Clinical-Events-Driven Clinical Trial--. --These Major Milestones Support the Advancement of Nebokitug to Phase 3 and Position It to Potentially Become the First FDA-Approved Treatment for PSC--. --Cash Runway Extended to the Second Quarter of 2026--. --Company Advancing Multiple Partnering Options for Executing the Nebokitug Program--. TEL AVIV, Israel, May 15, 2025  -- Chemomab Therapeutics Ltd., , a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2025, and provided a corporate update.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INN","BK4007","BK4218","BK6053","PSC","BK4022","BK4232","BK4539","LENZ","DM0.SI","R","BK4139","CMMB","BK4181","PK"],"gpt_icon":0},{"id":"2533586655","title":"Chemomab Therapeutics Ltd  expected to post a loss of 1 cent a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586655?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:04","pubTimestamp":1746446646,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics Ltd  expected to post a loss of 1cent a share - Earnings Preview Chemomab Therapeutics Ltd CMMB.OQ CMMB.O is expected to show no change in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD0TY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB"],"gpt_icon":0},{"id":"2532000582","title":"Biotech Alert: Searches spiking for these stocks today","url":"https://stock-news.laohu8.com/highlight/detail?id=2532000582","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532000582?lang=en_us&edition=fundamental","pubTime":"2025-05-02 00:15","pubTimestamp":1746116123,"startTime":"0","endTime":"0","summary":"These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:. Discover companies with rock-solid fundamentals in  TipRanks' Smart Value Newsletter.Receive undervalued stocks, resilient to market uncertainty,  delivered straight to your inbox.Tevogen Bio Holdings , 332% surge in interest. Pipeline and key clinical candidates for these companies:. Galmed is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. The company has focused almost exclusively on developing Aramchol for the treatment of noncirrhotic nonalcoholic steatohepatitis, or NASH, and are currently developing Aramchol for Primary Sclerosing Cholangitis, or PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease.CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-alert-searches-spiking-stocks-161523387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDAW","BK4532","LU0070302665.USD","BK4007","IE00BJJMRZ35.SGD","CMMB","LU0208291251.USD","TVGNW","LU0320765489.SGD","BK4578","CGON","BK4539","IE0002141913.USD","BCDA","RGLS","BK4139","BK4585","GLMD","IE0009355771.USD","LU0211331839.USD","SWTX","IE00BFTCPJ56.SGD","TVGN","BK4588","NVS","IE00B2B36J28.USD","MKKGY","IE00B4R5TH58.HKD","SNTI","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2531925815","title":"Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2531925815","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531925815?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:17","pubTimestamp":1745860632,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics  reported positive results from a Phase 2 trial of nebokitug, a treatment for primary sclerosing cholangitis and other fibro-inflammatory diseases.Patients treated with nebokitug exhibited significant changes in several proteins associated with fibrosis, inflammation and immune system activity with the effects increasing at higher doses, the company said Monday in a statement.The data showed that the nebokitug treatment reduced biological processes tied to fibrosis and inflammation, the company said.Nebokitug also lowered proteins involved in immune cell movement, inflammatory signals and collagen binding, the company said.Shares of the company rose 1.5% in recent Monday trading.Price: 1.33, Change: +0.02, Percent Change: +1.53","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LENZ","CMMB","BK4139"],"gpt_icon":0},{"id":"2530409113","title":"Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2530409113","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530409113?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers. Further Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Other Fibro-Inflammatory Conditions. Second EASL 2025 Poster Reports that Pharmacokinetic and Pharmacodynamic Data from the Phase 2 Spring Trial Demonstrates Effective and Dose-Dependent Antibody-Target Engagement. The second abstract presents an analysis of the pharmacodynamics and pharmacokinetics  of nebokitug and CCL24 using patient data from the Phase 2 SPRING trial in patients with PSC.2 PK analyses indicated dose-proportional increases in the concentration of nebokitug with steady-state","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-reports-positive-clinical-data-120000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4218","PSC","PK","CMMB","BK4181"],"gpt_icon":0},{"id":"2529806511","title":"Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2529806511","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529806511?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:00","pubTimestamp":1745236800,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, April 21, 2025  -- Chemomab Therapeutics, Ltd., , a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug  for the treatment of patients with primary sclerosing cholangitis  will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25, the British Society of Gastroenterology’s annual meeting. Chemomab will report information on the content of the presentations after the meeting embargoes lift.Oral presentation: CM-101, a novel monoclonal antibody targeting CCL24, was safe, well-tolerated and showed improvements of biomarkers associated with inflammation, fibrosis and cholestasis in patients with primary sclerosing cholangitis : The Spring Study. Paul Pockros, MD, Director, Liver Disease Scripps Clinic and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-therapeutics-present-nebokitug-clinical-120000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSC","LENZ","BK4007","CMMB","BK4139"],"gpt_icon":0},{"id":"2527446927","title":"Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527446927","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527446927?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:52","pubTimestamp":1744728774,"startTime":"0","endTime":"0","summary":"Chemomab Therapeutics  said Tuesday it has named David Weiner as interim chief medical officer, succeeding Matt Frankel.Weiner was interim CMO at Chemomab in 2021-2022 and has been a consultant to the company in the years since, the company said.Additionally, Jack Lawler, senior vice president of global medical operations at Chemomab, was appointed as chief development officer, the company said. Lawler joined Chemomab in 2022.Price: 1.17, Change: -0.03, Percent Change: -2.50","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","CMMB","LENZ"],"gpt_icon":0},{"id":"2527490299","title":"Chemomab Announces New Medical and Clinical Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2527490299","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527490299?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience. Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial inPSC, Assumes Chief Development Officer Role. Dr. Weiner commented, “I welcome the opportunity to rejoin Chemomab at this exciting time for the company. We have reported compelling clinical proof-of-concept data showing that nebokitug has the potential to become the first FDA-approved drug for PSC with disease-modifying activity and that it also may have potential in other fibro-inflammatory diseases. These are challenging times for o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-announces-medical-clinical-appointments-120000196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSC","BK4139","CMMB"],"gpt_icon":0},{"id":"2522370225","title":"BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers","url":"https://stock-news.laohu8.com/highlight/detail?id=2522370225","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522370225?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:32","pubTimestamp":1743078761,"startTime":"0","endTime":"0","summary":"BRIEF-Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver BiomarkersMarch 27 (Reuters) - Chemomab Th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA8QKXZ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMMB","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CMMB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"CMMB","fiscalQuarterEnding":"2025/03","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-03-03","symbol":"CMMB","fiscalQuarterEnding":"2024/12","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740978000000,"reportTimeType":"pre","actualEps":-0.16},{"market":"US","date":"2024-11-14","symbol":"CMMB","fiscalQuarterEnding":"2024/09","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2024-08-21","symbol":"CMMB","fiscalQuarterEnding":"2024/06","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1724212800000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2024-05-09","symbol":"CMMB","fiscalQuarterEnding":"2024/03","expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CMMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CMMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1715659200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CMMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CMMB","date":"2025-07-25","current":-1.558843,"percent":0.526415,"low":-98.872227,"twenty":-6.568553,"median":-1.653661,"eighty":-0.554344,"high":58.769136,"avg":-6.601536,"sd":13.410736,"marketCap":20888497},"quantilePoints":[{"date":"2021-03-19","current":-91.519729,"twenty":-35.539936,"median":48.429753,"eighty":54.633383,"marketCap":544633907},{"date":"2021-03-26","current":-55.781913,"twenty":-75.955442,"median":-57.552625,"eighty":6.745087,"marketCap":331958164},{"date":"2021-04-01","current":-50.766395,"twenty":-63.6845,"median":-54.253888,"eighty":-50.935377,"marketCap":302110814},{"date":"2021-04-09","current":-82.513368,"twenty":-79.007898,"median":-52.725862,"eighty":-48.975909,"marketCap":491037052},{"date":"2021-04-16","current":-49.004772,"twenty":-71.281483,"median":-56.204367,"eighty":-49.19171,"marketCap":291627398},{"date":"2021-04-23","current":-61.121139,"twenty":-69.57369,"median":-56.626821,"eighty":-50.104849,"marketCap":363731898},{"date":"2021-04-30","current":-53.139437,"twenty":-64.691225,"median":-57.669532,"eighty":-50.935377,"marketCap":316232791},{"date":"2021-05-07","current":-35.648005,"twenty":-63.397002,"median":-55.781913,"eighty":-48.78897,"marketCap":212141280},{"date":"2021-05-14","current":-30.514421,"twenty":-62.857698,"median":-53.74166,"eighty":-36.852451,"marketCap":181865949},{"date":"2021-05-21","current":-31.196508,"twenty":-62.433446,"median":-51.73714,"eighty":-34.423856,"marketCap":185931187},{"date":"2021-05-28","current":-31.770897,"twenty":-61.919309,"median":-50.550725,"eighty":-31.311386,"marketCap":189354546},{"date":"2021-06-04","current":-32.452984,"twenty":-61.588536,"median":-49.472118,"eighty":-30.848198,"marketCap":193419785},{"date":"2021-06-11","current":-42.935585,"twenty":-61.570559,"median":-46.829482,"eighty":-31.196508,"marketCap":255896088},{"date":"2021-06-18","current":-38.104027,"twenty":-61.121139,"median":-42.083702,"eighty":-31.250357,"marketCap":227100000},{"date":"2021-06-25","current":-38.307101,"twenty":-60.366113,"median":-41.39013,"eighty":-31.770897,"marketCap":228310320},{"date":"2021-07-02","current":-34.76254,"twenty":-58.478428,"median":-40.587065,"eighty":-32.322296,"marketCap":207184738},{"date":"2021-07-09","current":-34.984075,"twenty":-57.184194,"median":-39.848616,"eighty":-32.29343,"marketCap":208505087},{"date":"2021-07-16","current":-33.839477,"twenty":-56.673584,"median":-38.307101,"eighty":-32.29343,"marketCap":201683285},{"date":"2021-07-23","current":-32.731802,"twenty":-55.950895,"median":-36.540142,"eighty":-32.426846,"marketCap":195081541},{"date":"2021-07-30","current":-30.701064,"twenty":-54.861592,"median":-35.683959,"eighty":-31.801171,"marketCap":182978343},{"date":"2021-08-06","current":-30.257994,"twenty":-54.401409,"median":-35.427145,"eighty":-31.125673,"marketCap":180337645},{"date":"2021-08-13","current":-22.113138,"twenty":-53.380326,"median":-35.055685,"eighty":-30.686295,"marketCap":169143396},{"date":"2021-08-20","current":-18.134562,"twenty":-52.808577,"median":-34.734848,"eighty":-30.547239,"marketCap":138711262},{"date":"2021-08-27","current":-23.543638,"twenty":-51.934884,"median":-34.553094,"eighty":-30.2621,"marketCap":180085287},{"date":"2021-09-03","current":-21.830019,"twenty":-51.63647,"median":-34.004385,"eighty":-29.866616,"marketCap":166977813},{"date":"2021-09-10","current":-20.921056,"twenty":-51.104358,"median":-33.811785,"eighty":-29.763523,"marketCap":160025154},{"date":"2021-09-17","current":-19.356447,"twenty":-50.507592,"median":-33.72871,"eighty":-23.209855,"marketCap":148057460},{"date":"2021-09-24","current":-17.940848,"twenty":-50.0977,"median":-33.451791,"eighty":-22.083336,"marketCap":137229548},{"date":"2021-10-01","current":-16.09312,"twenty":-49.378648,"median":-32.787186,"eighty":-21.645246,"marketCap":123096272},{"date":"2021-10-08","current":-13.79836,"twenty":-48.842921,"median":-32.38764,"eighty":-20.041894,"marketCap":105543655},{"date":"2021-10-15","current":-13.545042,"twenty":-47.591697,"median":-32.177965,"eighty":-19.326645,"marketCap":103606029},{"date":"2021-10-22","current":-15.184156,"twenty":-44.493144,"median":-31.510627,"eighty":-18.820009,"marketCap":116143612},{"date":"2021-10-29","current":-14.971519,"twenty":-42.758824,"median":-31.144134,"eighty":-18.268671,"marketCap":114517146},{"date":"2021-11-05","current":-14.543412,"twenty":-42.16739,"median":-30.783862,"eighty":-18.057076,"marketCap":111242557},{"date":"2021-11-12","current":-11.785515,"twenty":-41.656517,"median":-30.627219,"eighty":-16.67426,"marketCap":110701340},{"date":"2021-11-19","current":-11.190777,"twenty":-41.444646,"median":-30.586219,"eighty":-15.443434,"marketCap":105114970},{"date":"2021-11-26","current":-10.765965,"twenty":-41.153826,"median":-30.524667,"eighty":-15.011304,"marketCap":101124705},{"date":"2021-12-03","current":-9.273052,"twenty":-40.769832,"median":-30.263126,"eighty":-14.901037,"marketCap":87101775},{"date":"2021-12-10","current":-9.697864,"twenty":-40.614757,"median":-30.137996,"eighty":-14.716264,"marketCap":91092040},{"date":"2021-12-17","current":-8.119989,"twenty":-40.24184,"median":-29.851847,"eighty":-14.22751,"marketCap":76271057},{"date":"2021-12-23","current":-9.151677,"twenty":-39.898461,"median":-29.778485,"eighty":-14.030817,"marketCap":85961700},{"date":"2021-12-31","current":-8.374877,"twenty":-39.710156,"median":-29.015625,"eighty":-13.774518,"marketCap":78665216},{"date":"2022-01-07","current":-8.171232,"twenty":-39.252317,"median":-22.70918,"eighty":-13.5212,"marketCap":76752379},{"date":"2022-01-14","current":-7.989109,"twenty":-38.266486,"median":-22.209995,"eighty":-11.707835,"marketCap":75041702},{"date":"2022-01-21","current":-6.54427,"twenty":-38.104027,"median":-21.98648,"eighty":-11.020852,"marketCap":61470330},{"date":"2022-01-28","current":-5.73079,"twenty":-37.180964,"median":-21.830019,"eighty":-10.620315,"marketCap":53829306},{"date":"2022-02-04","current":-5.524384,"twenty":-35.899319,"median":-20.950858,"eighty":-9.843514,"marketCap":51890538},{"date":"2022-02-11","current":-5.281554,"twenty":-35.881369,"median":-19.997191,"eighty":-9.564352,"marketCap":49609635},{"date":"2022-02-18","current":-4.68662,"twenty":-35.683959,"median":-19.468204,"eighty":-9.151677,"marketCap":44021424},{"date":"2022-02-25","current":-4.905167,"twenty":-35.655196,"median":-19.095678,"eighty":-8.816682,"marketCap":46074236},{"date":"2022-03-04","current":-4.832318,"twenty":-35.500855,"median":-18.849811,"eighty":-8.469356,"marketCap":45389965},{"date":"2022-03-11","current":-3.838673,"twenty":-35.404992,"median":-18.440033,"eighty":-8.377085,"marketCap":47898958},{"date":"2022-03-18","current":-4.094584,"twenty":-35.168688,"median":-18.223968,"eighty":-8.190926,"marketCap":51092222},{"date":"2022-03-25","current":-4.551569,"twenty":-35.067209,"median":-18.134562,"eighty":-7.9813,"marketCap":56794479},{"date":"2022-04-01","current":-4.414474,"twenty":-34.998397,"median":-17.806739,"eighty":-7.073639,"marketCap":55083807},{"date":"2022-04-08","current":-3.756416,"twenty":-34.806847,"median":-16.659359,"eighty":-6.204308,"marketCap":46872556},{"date":"2022-04-14","current":-3.482225,"twenty":-34.72931,"median":-16.301735,"eighty":-5.920197,"marketCap":43451202},{"date":"2022-04-22","current":-3.098358,"twenty":-34.657798,"median":-15.184156,"eighty":-5.670082,"marketCap":38661305},{"date":"2022-04-29","current":-2.879005,"twenty":-34.581814,"median":-15.020245,"eighty":-5.478246,"marketCap":35924222},{"date":"2022-05-06","current":-2.769328,"twenty":-34.456166,"median":-14.94574,"eighty":-5.310694,"marketCap":34555680},{"date":"2022-05-13","current":-2.003871,"twenty":-34.163888,"median":-14.878685,"eighty":-5.05815,"marketCap":31817456},{"date":"2022-05-20","current":-2.169142,"twenty":-34.002839,"median":-14.752026,"eighty":-4.844835,"marketCap":34441635},{"date":"2022-05-27","current":-2.176324,"twenty":-33.902348,"median":-14.580665,"eighty":-4.626514,"marketCap":34555680},{"date":"2022-06-03","current":-2.434898,"twenty":-33.817324,"median":-14.237941,"eighty":-4.492371,"marketCap":38661305},{"date":"2022-06-10","current":-2.715019,"twenty":-33.769325,"median":-14.066579,"eighty":-4.410209,"marketCap":43109066},{"date":"2022-06-17","current":-2.38462,"twenty":-33.739787,"median":-13.880316,"eighty":-4.319081,"marketCap":37862989},{"date":"2022-06-24","current":-2.944862,"twenty":-33.713941,"median":-13.783459,"eighty":-4.118347,"marketCap":46758511},{"date":"2022-07-01","current":-2.38462,"twenty":-33.643788,"median":-13.559943,"eighty":-3.866092,"marketCap":37862989},{"date":"2022-07-08","current":-2.485176,"twenty":-33.599481,"median":-13.51524,"eighty":-3.756416,"marketCap":39459621},{"date":"2022-07-15","current":-2.269698,"twenty":-33.304101,"median":-11.785515,"eighty":-3.62846,"marketCap":36038267},{"date":"2022-07-22","current":-2.327159,"twenty":-33.008721,"median":-11.22719,"eighty":-3.463945,"marketCap":36950628},{"date":"2022-07-29","current":-2.19069,"twenty":-32.787186,"median":-10.966233,"eighty":-3.116637,"marketCap":34783770},{"date":"2022-08-05","current":-2.513906,"twenty":-32.731802,"median":-10.765965,"eighty":-2.94127,"marketCap":39915802},{"date":"2022-08-12","current":-2.369501,"twenty":-32.452984,"median":-10.371496,"eighty":-2.888144,"marketCap":45726624},{"date":"2022-08-19","current":-1.978533,"twenty":-32.322296,"median":-9.843514,"eighty":-2.860251,"marketCap":38181731},{"date":"2022-08-26","current":-1.990381,"twenty":-32.177965,"median":-9.637176,"eighty":-2.779662,"marketCap":38410364},{"date":"2022-09-02","current":-2.008152,"twenty":-32.177965,"median":-9.479389,"eighty":-2.679106,"marketCap":38753313},{"date":"2022-09-09","current":-2.049618,"twenty":-31.882584,"median":-9.273052,"eighty":-2.612619,"marketCap":39553529},{"date":"2022-09-16","current":-1.777126,"twenty":-31.778465,"median":-8.927133,"eighty":-2.564697,"marketCap":34294968},{"date":"2022-09-23","current":-1.463167,"twenty":-31.354465,"median":-8.739002,"eighty":-2.498104,"marketCap":28236190},{"date":"2022-09-30","current":-1.475014,"twenty":-31.207278,"median":-8.515854,"eighty":-2.472247,"marketCap":28464823},{"date":"2022-10-07","current":-1.380234,"twenty":-31.154609,"median":-8.414062,"eighty":-2.410477,"marketCap":26635758},{"date":"2022-10-14","current":-1.18475,"twenty":-31.070289,"median":-8.376257,"eighty":-2.383874,"marketCap":22863312},{"date":"2022-10-21","current":-1.18475,"twenty":-30.888924,"median":-8.219798,"eighty":-2.366779,"marketCap":22863312},{"date":"2022-10-28","current":-1.19956,"twenty":-30.74526,"median":-8.177302,"eighty":-2.332598,"marketCap":23149103},{"date":"2022-11-04","current":-1.18475,"twenty":-30.704756,"median":-7.989109,"eighty":-2.268262,"marketCap":22863312},{"date":"2022-11-11","current":-0.982108,"twenty":-30.641988,"median":-7.738926,"eighty":-2.226603,"marketCap":23973258},{"date":"2022-11-18","current":-0.98683,"twenty":-30.623139,"median":-6.568553,"eighty":-2.207222,"marketCap":24088514},{"date":"2022-11-25","current":-0.973845,"twenty":-30.622119,"median":-6.337865,"eighty":-2.187817,"marketCap":23771560},{"date":"2022-12-02","current":-1.038768,"twenty":-30.57904,"median":-6.05861,"eighty":-2.171771,"marketCap":25356331},{"date":"2022-12-09","current":-1.133202,"twenty":-30.541076,"median":-5.876487,"eighty":-2.146158,"marketCap":27661452},{"date":"2022-12-16","current":-0.963221,"twenty":-30.522618,"median":-5.700436,"eighty":-2.044879,"marketCap":23512234},{"date":"2022-12-23","current":-1.114315,"twenty":-30.382719,"median":-5.597233,"eighty":-2.00644,"marketCap":27200427},{"date":"2022-12-30","current":-1.510936,"twenty":-30.282201,"median":-5.512242,"eighty":-1.983272,"marketCap":36881936},{"date":"2023-01-06","current":-1.067098,"twenty":-30.2621,"median":-5.41511,"eighty":-1.948914,"marketCap":26047867},{"date":"2023-01-13","current":-1.067098,"twenty":-30.239533,"median":-5.305837,"eighty":-1.937067,"marketCap":26047867},{"date":"2023-01-20","current":-1.067098,"twenty":-30.165688,"median":-5.269412,"eighty":-1.931143,"marketCap":26047867},{"date":"2023-01-27","current":-0.982108,"twenty":-30.110304,"median":-5.050865,"eighty":-1.853108,"marketCap":23973258},{"date":"2023-02-03","current":-1.048212,"twenty":-29.870308,"median":-4.879173,"eighty":-1.605337,"marketCap":25586843},{"date":"2023-02-10","current":-0.977386,"twenty":-29.851847,"median":-4.747328,"eighty":-1.480938,"marketCap":23858002},{"date":"2023-02-17","current":-0.925448,"twenty":-29.850284,"median":-4.624687,"eighty":-1.427624,"marketCap":22590185},{"date":"2023-02-24","current":-0.691463,"twenty":-29.792845,"median":-4.539264,"eighty":-1.380234,"marketCap":19116174},{"date":"2023-03-03","current":-0.671478,"twenty":-29.74856,"median":-4.460173,"eighty":-1.350616,"marketCap":18563684},{"date":"2023-03-10","current":-0.59154,"twenty":-29.297133,"median":-4.41092,"eighty":-1.241662,"marketCap":16353721},{"date":"2023-03-17","current":-0.587543,"twenty":-28.913312,"median":-4.377915,"eighty":-1.213184,"marketCap":16243223},{"date":"2023-03-24","current":-0.6435,"twenty":-24.603931,"median":-4.285951,"eighty":-1.204298,"marketCap":17790197},{"date":"2023-03-31","current":-0.635506,"twenty":-22.876072,"median":-4.094584,"eighty":-1.196586,"marketCap":17569201},{"date":"2023-04-06","current":-0.571556,"twenty":-22.530367,"median":-3.902651,"eighty":-1.18475,"marketCap":15801231},{"date":"2023-04-14","current":-0.631509,"twenty":-22.348575,"median":-3.847812,"eighty":-1.176457,"marketCap":17458702},{"date":"2023-04-21","current":-0.631509,"twenty":-22.190624,"median":-3.756416,"eighty":-1.136035,"marketCap":17458702},{"date":"2023-04-28","current":-0.611525,"twenty":-22.068435,"median":-3.669588,"eighty":-1.107705,"marketCap":16906212},{"date":"2023-05-05","current":-0.575553,"twenty":-21.976049,"median":-3.591901,"eighty":-1.091651,"marketCap":15911729},{"date":"2023-05-12","current":-0.645498,"twenty":-21.904524,"median":-3.482225,"eighty":-1.080319,"marketCap":17845446},{"date":"2023-05-19","current":-0.649677,"twenty":-21.8479,"median":-3.422817,"eighty":-1.070403,"marketCap":20331654},{"date":"2023-05-26","current":-0.57906,"twenty":-21.645246,"median":-3.116637,"eighty":-1.067098,"marketCap":18121691},{"date":"2023-06-02","current":-0.564937,"twenty":-21.290602,"median":-2.980774,"eighty":-1.057655,"marketCap":17679699},{"date":"2023-06-09","current":-0.6179,"twenty":-20.968739,"median":-2.932987,"eighty":-1.044434,"marketCap":19337171},{"date":"2023-06-15","current":-0.600245,"twenty":-20.921056,"median":-2.919439,"eighty":-1.034046,"marketCap":18784680},{"date":"2023-06-23","current":-0.473135,"twenty":-20.241568,"median":-2.883574,"eighty":-1.018937,"marketCap":14806748},{"date":"2023-06-30","current":-0.430764,"twenty":-20.026993,"median":-2.869865,"eighty":-0.989663,"marketCap":13480770},{"date":"2023-07-07","current":-0.459011,"twenty":-19.913745,"median":-2.851348,"eighty":-0.982108,"marketCap":14364755},{"date":"2023-07-14","current":-0.49432,"twenty":-19.705131,"median":-2.822757,"eighty":-0.977386,"marketCap":15469736},{"date":"2023-07-21","current":-0.480196,"twenty":-19.490556,"median":-2.763721,"eighty":-0.967943,"marketCap":15027744},{"date":"2023-07-28","current":-0.45548,"twenty":-19.341546,"median":-2.697062,"eighty":-0.963221,"marketCap":14254257},{"date":"2023-08-04","current":-0.441357,"twenty":-19.207436,"median":-2.650375,"eighty":-0.95,"marketCap":13812265},{"date":"2023-08-11","current":-0.416641,"twenty":-18.903456,"median":-2.603688,"eighty":-0.926392,"marketCap":13038778},{"date":"2023-08-18","current":-0.350788,"twenty":-18.873653,"median":-2.577395,"eighty":-0.820525,"marketCap":11602302},{"date":"2023-08-25","current":-0.371693,"twenty":-18.83491,"median":-2.513906,"eighty":-0.685068,"marketCap":12293748},{"date":"2023-09-01","current":-0.396711,"twenty":-18.775306,"median":-2.49595,"eighty":-0.671478,"marketCap":13121212},{"date":"2023-09-08","current":-0.375267,"twenty":-18.596494,"median":-2.485176,"eighty":-0.653892,"marketCap":12411957},{"date":"2023-09-15","current":-0.382415,"twenty":-18.432582,"median":-2.463628,"eighty":-0.647497,"marketCap":12648375},{"date":"2023-09-22","current":-0.375267,"twenty":-18.361057,"median":-2.434898,"eighty":-0.647497,"marketCap":12411957},{"date":"2023-09-27","current":-0.332236,"twenty":-18.319334,"median":-2.424124,"eighty":-0.647097,"marketCap":10988719},{"date":"2023-10-06","current":-0.297676,"twenty":-18.238869,"median":-2.391802,"eighty":-0.639503,"marketCap":9845637},{"date":"2023-10-13","current":-0.31987,"twenty":-18.197146,"median":-2.38462,"eighty":-0.635506,"marketCap":10579716},{"date":"2023-10-20","current":-0.300214,"twenty":-18.152443,"median":-2.373845,"eighty":-0.631509,"marketCap":9929566},{"date":"2023-10-27","current":-0.293209,"twenty":-18.134562,"median":-2.369878,"eighty":-0.631509,"marketCap":9697876},{"date":"2023-11-03","current":-0.271479,"twenty":-18.134562,"median":-2.348707,"eighty":-0.623515,"marketCap":8979164},{"date":"2023-11-10","current":-0.214438,"twenty":-17.940848,"median":-2.330558,"eighty":-0.619518,"marketCap":7092547},{"date":"2023-11-17","current":-0.268324,"twenty":-17.806739,"median":-2.284063,"eighty":-0.615522,"marketCap":7801801},{"date":"2023-11-24","current":-0.225636,"twenty":-17.38951,"median":-2.262516,"eighty":-0.611525,"marketCap":6560606},{"date":"2023-12-01","current":-0.219132,"twenty":-16.844132,"median":-2.23375,"eighty":-0.607528,"marketCap":6371471},{"date":"2023-12-08","current":-0.195186,"twenty":-16.614656,"median":-2.212237,"eighty":-0.602874,"marketCap":5675219},{"date":"2023-12-15","current":-0.20287,"twenty":-16.52525,"median":-2.203715,"eighty":-0.59911,"marketCap":5898635},{"date":"2023-12-22","current":-0.199211,"twenty":-16.176566,"median":-2.19069,"eighty":-0.595537,"marketCap":5792246},{"date":"2023-12-29","current":-0.215473,"twenty":-15.902386,"median":-2.179915,"eighty":-0.59154,"marketCap":6265083},{"date":"2024-01-05","current":-0.215473,"twenty":-15.616286,"median":-2.176324,"eighty":-0.583546,"marketCap":6265083},{"date":"2024-01-12","current":-0.227588,"twenty":-15.184156,"median":-2.169142,"eighty":-0.575553,"marketCap":6617346},{"date":"2024-01-19","current":-0.217912,"twenty":-15.136473,"median":-2.154777,"eighty":-0.57191,"marketCap":6336008},{"date":"2024-01-26","current":-0.20413,"twenty":-15.076869,"median":-2.114779,"eighty":-0.557875,"marketCap":5935279},{"date":"2024-02-02","current":-0.231491,"twenty":-14.993423,"median":-2.043694,"eighty":-0.501381,"marketCap":6730827},{"date":"2024-02-09","current":-0.243931,"twenty":-14.972324,"median":-2.011125,"eighty":-0.494052,"marketCap":7092547},{"date":"2024-02-16","current":-0.247997,"twenty":-14.950896,"median":-2.00305,"eighty":-0.485846,"marketCap":7210756},{"date":"2024-02-23","current":-0.304914,"twenty":-14.932329,"median":-1.984457,"eighty":-0.475253,"marketCap":8865684},{"date":"2024-03-01","current":-0.278488,"twenty":-14.901037,"median":-1.948914,"eighty":-0.459011,"marketCap":8097324},{"date":"2024-03-08","current":-0.390435,"twenty":-14.877195,"median":-1.940029,"eighty":-0.451949,"marketCap":9456729},{"date":"2024-03-15","current":-0.486178,"twenty":-14.817591,"median":-1.937067,"eighty":-0.451949,"marketCap":11775725},{"date":"2024-03-22","current":-0.462661,"twenty":-14.763947,"median":-1.932624,"eighty":-0.451949,"marketCap":11206115},{"date":"2024-03-28","current":-0.451577,"twenty":-14.728184,"median":-1.922257,"eighty":-0.451601,"marketCap":10937645},{"date":"2024-04-05","current":-0.457442,"twenty":-14.66262,"median":-1.853108,"eighty":-0.451601,"marketCap":11079693},{"date":"2024-04-12","current":-0.445712,"twenty":-14.588115,"median":-1.655689,"eighty":-0.451601,"marketCap":10795598},{"date":"2024-04-19","current":-0.410525,"twenty":-14.442085,"median":-1.587565,"eighty":-0.446181,"marketCap":9943314},{"date":"2024-04-26","current":-0.38648,"twenty":-14.248371,"median":-1.495937,"eighty":-0.441357,"marketCap":9360920},{"date":"2024-05-03","current":-0.431168,"twenty":-14.162243,"median":-1.463167,"eighty":-0.433831,"marketCap":10443321},{"date":"2024-05-10","current":-0.475036,"twenty":-14.102788,"median":-1.412815,"eighty":-0.432294,"marketCap":11505835},{"date":"2024-05-17","current":-0.639125,"twenty":-14.048698,"median":-1.380234,"eighty":-0.43552,"marketCap":12358119},{"date":"2024-05-24","current":-0.61697,"twenty":-13.980153,"median":-1.37476,"eighty":-0.437826,"marketCap":11929739},{"date":"2024-05-31","current":-0.779486,"twenty":-13.902667,"median":-1.323959,"eighty":-0.438113,"marketCap":15072137},{"date":"2024-06-07","current":-0.838241,"twenty":-13.834122,"median":-1.249912,"eighty":-0.43968,"marketCap":16208235},{"date":"2024-06-14","current":-0.845669,"twenty":-13.79836,"median":-1.232357,"eighty":-0.441357,"marketCap":16351847},{"date":"2024-06-21","current":-0.683888,"twenty":-13.774518,"median":-1.222913,"eighty":-0.441357,"marketCap":13223668},{"date":"2024-06-28","current":-0.714039,"twenty":-13.732795,"median":-1.214369,"eighty":-0.441357,"marketCap":13806661},{"date":"2024-07-05","current":-0.711465,"twenty":-13.589745,"median":-1.208445,"eighty":-0.441357,"marketCap":13756880},{"date":"2024-07-12","current":-0.838315,"twenty":-13.559943,"median":-1.202522,"eighty":-0.441357,"marketCap":16209657},{"date":"2024-07-15","current":-0.815592,"twenty":-13.556963,"median":-1.19956,"eighty":-0.442228,"marketCap":15770290},{"date":"2024-08-02","current":-0.856699,"twenty":-13.553983,"median":-1.199412,"eighty":-0.443099,"marketCap":16565132},{"date":"2024-08-09","current":-0.742791,"twenty":-13.533121,"median":-1.196598,"eighty":-0.446181,"marketCap":14362609},{"date":"2024-08-16","current":-0.794193,"twenty":-13.061245,"median":-1.187712,"eighty":-0.44712,"marketCap":15356517},{"date":"2024-08-23","current":-1.15671,"twenty":-12.142357,"median":-1.18475,"eighty":-0.449067,"marketCap":17347177},{"date":"2024-08-30","current":-1.876643,"twenty":-11.785515,"median":-1.187712,"eighty":-0.451507,"marketCap":28144012},{"date":"2024-09-06","current":-2.192608,"twenty":-11.766095,"median":-1.196569,"eighty":-0.451589,"marketCap":32882545},{"date":"2024-09-13","current":-1.914942,"twenty":-11.59617,"median":-1.199263,"eighty":-0.451699,"marketCap":28718380},{"date":"2024-09-20","current":-1.608551,"twenty":-11.219907,"median":-1.206964,"eighty":-0.451949,"marketCap":24123439},{"date":"2024-09-27","current":-1.503229,"twenty":-11.156792,"median":-1.208445,"eighty":-0.451949,"marketCap":22543928},{"date":"2024-10-04","current":-1.445781,"twenty":-10.999005,"median":-1.224565,"eighty":-0.452015,"marketCap":21682376},{"date":"2024-10-11","current":-1.148965,"twenty":-10.88734,"median":-1.232357,"eighty":-0.452921,"marketCap":17231028},{"date":"2024-10-18","current":-1.225563,"twenty":-10.785385,"median":-1.22589,"eighty":-0.45548,"marketCap":18379763},{"date":"2024-10-25","current":-1.378758,"twenty":-10.736835,"median":-1.235137,"eighty":-0.455755,"marketCap":20677233},{"date":"2024-10-31","current":-1.359609,"twenty":-10.620315,"median":-1.249912,"eighty":-0.456855,"marketCap":20390049},{"date":"2024-11-08","current":-1.417057,"twenty":-10.45039,"median":-1.266908,"eighty":-0.457442,"marketCap":21251601},{"date":"2024-11-15","current":-1.665999,"twenty":-10.292602,"median":-1.32131,"eighty":-0.459011,"marketCap":24984990},{"date":"2024-11-22","current":-2.095324,"twenty":-10.231915,"median":-1.363998,"eighty":-0.459011,"marketCap":30170577},{"date":"2024-11-29","current":-2.383432,"twenty":-9.921194,"median":-1.369183,"eighty":-0.461931,"marketCap":34319032},{"date":"2024-12-06","current":-2.160803,"twenty":-9.756124,"median":-1.373971,"eighty":-0.462708,"marketCap":31113408},{"date":"2024-12-13","current":-2.213186,"twenty":-9.705147,"median":-1.378758,"eighty":-0.463189,"marketCap":31867672},{"date":"2024-12-20","current":-2.121516,"twenty":-9.600764,"median":-1.380234,"eighty":-0.463306,"marketCap":30547709},{"date":"2024-12-27","current":-2.60606,"twenty":-9.569207,"median":-1.380234,"eighty":-0.463517,"marketCap":37524655},{"date":"2025-01-03","current":-2.789401,"twenty":-9.530367,"median":-1.398005,"eighty":-0.464624,"marketCap":40164581},{"date":"2025-01-10","current":-2.907263,"twenty":-9.476962,"median":-1.417057,"eighty":-0.466165,"marketCap":41861676},{"date":"2025-01-17","current":-2.553677,"twenty":-9.428412,"median":-1.440994,"eighty":-0.466978,"marketCap":36770391},{"date":"2025-01-24","current":-2.776305,"twenty":-9.273052,"median":-1.445781,"eighty":-0.46876,"marketCap":39976015},{"date":"2025-01-31","current":-2.671539,"twenty":-9.151677,"median":-1.455356,"eighty":-0.469171,"marketCap":38467486},{"date":"2025-02-07","current":-2.737018,"twenty":-9.018164,"median":-1.469718,"eighty":-0.473135,"marketCap":39410316},{"date":"2025-02-14","current":-2.592964,"twenty":-8.836102,"median":-1.480938,"eighty":-0.473135,"marketCap":37336089},{"date":"2025-02-21","current":-2.317953,"twenty":-8.836102,"median":-1.503229,"eighty":-0.473248,"marketCap":33376201},{"date":"2025-02-28","current":-2.121516,"twenty":-8.758422,"median":-1.503229,"eighty":-0.474684,"marketCap":30547709},{"date":"2025-03-07","current":-2.001275,"twenty":-8.680742,"median":-1.510936,"eighty":-0.476339,"marketCap":27907784},{"date":"2025-03-14","current":-1.879576,"twenty":-8.578787,"median":-1.515197,"eighty":-0.47949,"marketCap":26210689},{"date":"2025-03-21","current":-1.825488,"twenty":-8.491203,"median":-1.551103,"eighty":-0.480196,"marketCap":25456424},{"date":"2025-03-28","current":-1.487434,"twenty":-8.453115,"median":-1.55589,"eighty":-0.482636,"marketCap":20742272},{"date":"2025-04-04","current":-1.446868,"twenty":-8.42079,"median":-1.528001,"eighty":-0.483668,"marketCap":20176573},{"date":"2025-04-11","current":-1.27108,"twenty":-8.411844,"median":-1.519998,"eighty":-0.485697,"marketCap":17725214},{"date":"2025-04-17","current":-1.568567,"twenty":-8.391098,"median":-1.525203,"eighty":-0.486826,"marketCap":21873668},{"date":"2025-04-25","current":-1.744355,"twenty":-8.375981,"median":-1.528001,"eighty":-0.487258,"marketCap":24325028},{"date":"2025-05-02","current":-1.852532,"twenty":-8.369248,"median":-1.55589,"eighty":-0.487258,"marketCap":25833557},{"date":"2025-05-09","current":-1.663222,"twenty":-8.278077,"median":-1.568567,"eighty":-0.49069,"marketCap":23193631},{"date":"2025-05-16","current":-1.815301,"twenty":-8.203608,"median":-1.575039,"eighty":-0.493783,"marketCap":24325028},{"date":"2025-05-23","current":-1.913805,"twenty":-8.187149,"median":-1.582089,"eighty":-0.49432,"marketCap":25644990},{"date":"2025-05-30","current":-1.948554,"twenty":-8.178517,"median":-1.596287,"eighty":-0.495732,"marketCap":26110621},{"date":"2025-06-06","current":-1.887773,"twenty":-8.150735,"median":-1.606944,"eighty":-0.498765,"marketCap":25296161},{"date":"2025-06-13","current":-1.74476,"twenty":-8.067637,"median":-1.629032,"eighty":-0.500634,"marketCap":23379785},{"date":"2025-06-20","current":-1.74476,"twenty":-7.9813,"median":-1.636178,"eighty":-0.501381,"marketCap":23379785},{"date":"2025-06-27","current":-1.707005,"twenty":-7.916079,"median":-1.655456,"eighty":-0.501977,"marketCap":22873862},{"date":"2025-07-03","current":-1.658952,"twenty":-7.780139,"median":-1.658952,"eighty":-0.504359,"marketCap":22229960},{"date":"2025-07-11","current":-1.658952,"twenty":-7.697713,"median":-1.658952,"eighty":-0.52119,"marketCap":22229960},{"date":"2025-07-18","current":-1.616048,"twenty":-7.199911,"median":-1.658952,"eighty":-0.533159,"marketCap":21655047},{"date":"2025-07-25","current":-1.558843,"twenty":-6.568553,"median":-1.653661,"eighty":-0.554344,"marketCap":20888497}],"updateTime":1753538700226}}}